Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “improving” the drug. They’re extending it. Here are 4 signals to watch.
In pharma, the most consequential moves rarely look dramatic. They don’t always come with splashy press releases or blockbuster trial headlines. Often, they …

Biopharma teams don’t lose deals because they lack ambition. They lose because they’re late—late to the market, late to the narrative, late to the regulatory clock that quietly governs everything from labeling to packaging to launch readiness.
That’s t…

GPT, Rosalind, and the Real Question for Drug Development: What Changes—And What Doesn’t?
The life sciences community is buzzing again—this time around OpenAI’s “Rosalind,” a model positioned to accelerate drug discovery. The pitch is compelling: faste…

Most pharma teams treat biosimilar outreach like a calendar event. That’s why they miss the window.
Patent expiry intelligence isn’t just for forecasting timelines—it’s for timing conversations. And right now, the biggest opportunity in biosimilars isn…

Drug patents in Europe: the protection window is shorter—and more fragile—than most people think
Most people think a European drug patent is a long, predictable moat: file today, enjoy exclusivity for years, and ride the wave. In reality, the protectio…

Drug discovery timelines are getting longer—until they aren’t.
For years, the industry’s story has been familiar: target identification takes months, hit finding takes longer, and the “time-to-clinic” gap keeps widening as biology refuses to cooperate …

The “Patent Expiration Cliff” Isn’t a Cliff—It’s a Calendar. Here’s How Commercial Market Access Teams Can Sell Before the Fall.
If you’re in commercial market access, you’ve felt it: the sudden squeeze when exclusivity ends, generics arrive, and prici…

Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
In the patent world, the first filer often gets the headlines—new entrants, big bets, and the promise of exclusivity. But there’s a quieter strategy that can reshape the eco…

The clock is ticking—and “generic” isn’t a single moment. It’s a timeline.
If you’re building a true generic entry strategy, the biggest risk isn’t whether your product can win scientifically—it’s whether it can win on time. In today’s regulatory env…